Revance Therapeutics Overview
Revance Therapeutics (RVNC) has a ROE of 111.29%, above the Healthcare sector average of 21.67%.
Get informed when a big investor buys or sells
+ Follow111.29%
Return on Equity measures how efficiently a company uses shareholders' equity to generate profits. A higher ROE indicates better profitability relative to equity.
As of the most recent data, RVNC shows a ROE of 111.29%. That is above the Healthcare sector average of 21.67%. Scroll down for historical charts and peer comparison views.
The Healthcare sector average ROE is about 21.67%. Revance Therapeutics is at 111.29%, which is higher that average. That is roughly 413.6% above the sector mean. Use the comparison chart on this page to see how RVNC stacks up against individual peers as well.
Check the historical chart to see whether RVNC's ROE is trending up or down. Improvement over multiple periods is generally more meaningful than a single strong quarter. Compare Revance Therapeutics with peers to see if the move is company-specific or sector-wide.
Besides this return on equity page, Stockcircle has Revance Therapeutics's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect ROE (currently 111.29%) with ownership activity and broader fundamentals.
The Healthcare average ROE is about 21.67%, while RVNC is at 111.29%. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.
